WASHINGTON & BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis. These data were presented today at the American Association for Cancer Research Annual Meeting in Washington DC. PLX3397 is currently being evaluated in a Phase 1 clinical trial for metastatic solid tumors.
